Drug discovery teams often lack human pharmacokinetic insight early enough to guide compound prioritization, which can lead ...
It may sound harsh, but drug candidates that are bound to be poor performers should be identified sooner rather than later—and ruthlessly eliminated from development. Granted, early in development, ...
DUBLIN--(BUSINESS WIRE)--The "ADME Toxicology Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's ...
DUBLIN--(BUSINESS WIRE)--The "ADME-Toxicology Testing: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. Global ADME-Toxicology Testing Market to Reach ...
The in vitro assays from CN-Bio are effective in predicting clinical outcomes. High-functioning, metabolically competent human single- and multi-organ models are used in studies on drug metabolism, ...
New co-developed product delivers a complete Tier 1 ADME panel coupled with best-in-class AI-driven human pharmacokinetic (PK) projection and integrated compound management —enabling scientists to ...
The ADME/DMPK services at Ace Therapeutics include a comprehensive suite of in vitro and in vivo ADME studies to assess the absorption, distribution, metabolism, and excretion of drug candidates, as ...
Can you give a brief overview of Lonza, the markets you serve and the types of products that you produce? Lonza is a large, multinational corporation serving the entire pharmaceutical product ...
Fail fast, fail cheap is a common clich in drug development. Studies project that anywhere from 4060% of potential drugs candidates fail in development due to absorption, distribution, metabolism, ...
Emulate, Inc., the leading provider of next-generation in vitro Organ-Chip models, today announced the release of its new Chip-R1™ Rigid Chip, designed to minimize drug absorption and enhance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results